Psoriasis, metabolic syndrome and methotrexate: Is this association suitable for a new subcategory in steatotic liver disease?

doi:10.4254/wjh.v17.i4.102978

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Sum=0

Apr 27, 2025 (publication date) through Apr 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Apr 27, 2025; 17(4): 102978
Published online Apr 27, 2025. doi: 10.4254/wjh.v17.i4.102978

Full Size Figure Download Figure

Figure 1 Proposal of metabolic and drug-induced steatotic liver disease subcategory. SLD: Steatotic liver disease; MASLD: Metabolic-dysfunction associated steatotic liver disease; MetALD: Metabolic-dysfunction associated steatotic liver disease and alcohol-related liver disease.

Citation: Agoglia L, Chindamo MC, Villela-Nogueira C. Psoriasis, metabolic syndrome and methotrexate: Is this association suitable for a new subcategory in steatotic liver disease? World J Hepatol 2025; 17(4): 102978
URL: https://www.wjgnet.com/1948-5182/full/v17/i4/102978.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i4.102978